Skip to main content
NCBI home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2022;2434:235–243. doi: 10.1007/978-1-0716-2010-6_15

Generation of Human iPSC-Derived Myotubes to Investigate RNA-Based Therapies In Vitro.

Pablo Herrero-Hernandez, Atze J Bergsma, W W M Pim Pijnappel
PMCID: PMC9703849  PMID: 35213021

Abstract

Alternative pre-mRNA splicing can be cell-type specific and results in the generation of different protein isoforms from a single gene. Deregulation of canonical pre-mRNA splicing by disease-associated variants can result in genetic disorders. Antisense oligonucleotides (AONs) offer an attractive solution to modulate endogenous gene expression through alteration of pre-mRNA splicing events. Relevant in vitro models are crucial for appropriate evaluation of splicing modifying drugs. In this chapter, we describe how to investigate the splicing modulating activity of AONs in an in vitro skeletal muscle model, applied to Pompe disease. We also provide a detailed description of methods to visualize and analyze gene expression in differentiated skeletal muscle cells for the analysis of muscle differentiation and splicing outcome. The methodology described here is relevant to develop treatment options using AONs for other genetic muscle diseases as well, including Duchenne muscular dystrophy, myotonic dystrophy, and facioscapulohumeral muscular dystrophy.

Full text of this article can be found in Bookshelf.

References

  1. Shapiro MB, Senapathy P (1987) RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res 15(17):7155–7174. https://doi.org/10.1093/nar/15.17.7155 doi: 10.1093/nar/15.17.7155. [DOI] [PMC free article] [PubMed]
  2. Lei Q, Li C, Zuo Z, Huang C, Cheng H, Zhou R (2016) Evolutionary insights into RNA trans-splicing in vertebrates. Genome Biol Evol 8(3):562–577. https://doi.org/10.1093/gbe/evw025 doi: 10.1093/gbe/evw025. [DOI] [PMC free article] [PubMed]
  3. Bergsma AJ, van der Wal E, Broeders M, van der Ploeg AT, Pim Pijnappel WWM (2018) Alternative splicing in genetic diseases: improved diagnosis and novel treatment options. Int Rev Cell Mol Biol 335:85–141. https://doi.org/10.1016/bs.ircmb.2017.07.008 doi: 10.1016/bs.ircmb.2017.07.008. [DOI] [PubMed]
  4. van der Wal E, Bergsma AJ, Pijnenburg JM, van der Ploeg AT, Pijnappel W (2017) Antisense oligonucleotides promote exon inclusion and correct the common c.-32-13T>G GAA splicing variant in Pompe disease. Mol Ther Nucleic Acids 7:90–100. https://doi.org/10.1016/j.omtn.2017.03.001 doi: 10.1016/j.omtn.2017.03.001. [DOI] [PMC free article] [PubMed]
  5. Pistoni M, Ghigna C, Gabellini D (2010) Alternative splicing and muscular dystrophy. RNA Biol 7(4):441–452. https://doi.org/10.4161/rna.7.4.12258 doi: 10.4161/rna.7.4.12258. [DOI] [PMC free article] [PubMed]
  6. Baghdadi MB, Tajbakhsh S (2018) Regulation and phylogeny of skeletal muscle regeneration. Dev Biol 433(2):200–209. https://doi.org/10.1016/j.ydbio.2017.07.026 doi: 10.1016/j.ydbio.2017.07.026. [DOI] [PubMed]
  7. Ito N, Kii I, Shimizu N, Tanaka H, Takeda S (2017) Direct reprogramming of fibroblasts into skeletal muscle progenitor cells by transcription factors enriched in undifferentiated subpopulation of satellite cells. Sci Rep 7(1):8097. https://doi.org/10.1038/s41598-017-08232-2 doi: 10.1038/s41598-017-08232-2. [DOI] [PMC free article] [PubMed]
  8. Selvaraj S, Kyba M, Perlingeiro RCR (2019) Pluripotent stem cell-based therapeutics for muscular dystrophies. Trends Mol Med 25(9):803–816. https://doi.org/10.1016/j.molmed.2019.07.004 doi: 10.1016/j.molmed.2019.07.004. [DOI] [PMC free article] [PubMed]
  9. Choi IY, Lim H, Estrellas K, Mula J, Cohen TV, Zhang Y, Donnelly CJ, Richard JP, Kim YJ, Kim H, Kazuki Y, Oshimura M, Li HL, Hotta A, Rothstein J, Maragakis N, Wagner KR, Lee G (2016) Concordant but varied phenotypes among Duchenne muscular dystrophy patient-specific myoblasts derived using a human iPSC-based model. Cell Rep 15(10):2301–2312. https://doi.org/10.1016/j.celrep.2016.05.016 doi: 10.1016/j.celrep.2016.05.016. [DOI] [PubMed]
  10. Hicks MR, Hiserodt J, Paras K, Fujiwara W, Eskin A, Jan M, Xi H, Young CS, Evseenko D, Nelson SF, Spencer MJ, Handel BV, Pyle AD (2018) ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol 20(1):46–57. https://doi.org/10.1038/s41556-017-0010-2 doi: 10.1038/s41556-017-0010-2. [DOI] [PMC free article] [PubMed]
  11. van der Wal E, Herrero-Hernandez P, Wan R, Broeders M, In ‘t Groen SLM, van Gestel TJM, van Ijcken WFJ, Cheung TH, van der Ploeg AT, Schaaf GJ, Pijnappel W (2018) Large-scale expansion of human iPSC-derived skeletal muscle cells for disease modeling and cell-based therapeutic strategies. Stem cell Rep 10(6):1975–1990. https://doi.org/10.1016/j.stemcr.2018.04.002 doi: 10.1016/j.stemcr.2018.04.002. [DOI] [PMC free article] [PubMed]
  12. van der Wal E, Bergsma AJ, van Gestel TJM, In ‘t Groen SLM, Zaehres H, Arauzo-Bravo MJ, Scholer HR, van der Ploeg AT, Pijnappel W (2017) GAA deficiency in Pompe disease is alleviated by exon inclusion in iPSC-derived skeletal muscle cells. Mol Ther Nucleic Acids 7:101–115. https://doi.org/10.1016/j.omtn.2017.03.002 doi: 10.1016/j.omtn.2017.03.002. [DOI] [PMC free article] [PubMed]

RESOURCES